These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

286 related items for PubMed ID: 19744422

  • 1. Selecting among ADA/EASD tier 1 and tier 2 treatment options.
    McGill JB.
    J Fam Pract; 2009 Sep; 58(9 Suppl Treating):S26-34. PubMed ID: 19744422
    [Abstract] [Full Text] [Related]

  • 2. Balancing risk and benefit with oral hypoglycemic drugs.
    Hamnvik OP, McMahon GT.
    Mt Sinai J Med; 2009 Jun; 76(3):234-43. PubMed ID: 19421967
    [Abstract] [Full Text] [Related]

  • 3. Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies.
    Penfornis A, Borot S, Raccah D.
    Diabetes Metab; 2008 Feb; 34 Suppl 2():S78-90. PubMed ID: 18640590
    [Abstract] [Full Text] [Related]

  • 4. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?
    Halimi S.
    Diabetes Metab; 2008 Feb; 34 Suppl 2():S91-5. PubMed ID: 18640591
    [Abstract] [Full Text] [Related]

  • 5. Race, ethnicity, and use of thiazolidinediones among US adults with diabetes.
    Aquilante CL, Zhang W, McCollum M.
    Curr Med Res Opin; 2007 Mar; 23(3):489-94. PubMed ID: 17355730
    [Abstract] [Full Text] [Related]

  • 6. Managing type 2 diabetes: going beyond glycemic control.
    Stolar MW, Hoogwerf BJ, Gorshow SM, Boyle PJ, Wales DO.
    J Manag Care Pharm; 2008 Jun; 14(5 Suppl B):s2-19. PubMed ID: 18597582
    [Abstract] [Full Text] [Related]

  • 7. Practical applications of therapy with a glucagon-like peptide-1 receptor agonist.
    Shomali ME.
    J Fam Pract; 2009 Sep; 58(9 Suppl Treating):S35-43. PubMed ID: 19744424
    [Abstract] [Full Text] [Related]

  • 8. Incorporating incretin-based therapies into clinical practice: differences between glucagon-like Peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors.
    Davidson JA.
    Mayo Clin Proc; 2010 Dec; 85(12 Suppl):S27-37. PubMed ID: 21106865
    [Abstract] [Full Text] [Related]

  • 9. Rationale and design of the Glitazones and the Endothelium (GATE) study: evaluation of rosiglitazone on endothelial function in patients with diabetes.
    Hubacek J, Verma S, Shewchuk L, Ross SJ, Edwards A, Anderson TJ.
    Can J Cardiol; 2004 Dec; 20(14):1449-53. PubMed ID: 15614340
    [Abstract] [Full Text] [Related]

  • 10. Oral antidiabetic agents: 2004.
    Lebovitz HE.
    Med Clin North Am; 2004 Jul; 88(4):847-63, ix-x. PubMed ID: 15308382
    [Abstract] [Full Text] [Related]

  • 11. Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease.
    Snyder RW, Berns JS.
    Semin Dial; 2004 Jul; 17(5):365-70. PubMed ID: 15461745
    [Abstract] [Full Text] [Related]

  • 12. When oral agents fail: optimizing insulin therapy in the older adult.
    Meece J.
    Consult Pharm; 2009 Jun; 24 Suppl B():11-7. PubMed ID: 19555131
    [Abstract] [Full Text] [Related]

  • 13. Patient and treatment perspectives: Revisiting the link between type 2 diabetes, weight gain, and cardiovascular risk.
    Peters AL.
    Cleve Clin J Med; 2009 Dec; 76 Suppl 5():S20-7. PubMed ID: 19952300
    [Abstract] [Full Text] [Related]

  • 14. Initiating insulin in patients with type 2 diabetes.
    Aoki TJ, White RD.
    J Fam Pract; 2007 Aug; 56(8 Suppl Hot Topics):S12-20. PubMed ID: 18667139
    [Abstract] [Full Text] [Related]

  • 15. New technologies and therapies in the management of diabetes.
    Triplitt CL.
    Am J Manag Care; 2007 Apr; 13 Suppl 2():S47-54. PubMed ID: 17417933
    [Abstract] [Full Text] [Related]

  • 16. Avoiding hypoglycaemia while achieving good glycaemic control in type 2 diabetes through optimal use of oral agent therapy.
    Barnett AH.
    Curr Med Res Opin; 2010 Jun; 26(6):1333-42. PubMed ID: 20370379
    [Abstract] [Full Text] [Related]

  • 17. Hypoglycemia in type 2 diabetes.
    Banarer S, Cryer PE.
    Med Clin North Am; 2004 Jul; 88(4):1107-16, xii-xiii. PubMed ID: 15308392
    [Abstract] [Full Text] [Related]

  • 18. In-hospital management of type 2 diabetes mellitus.
    Lien LF, Angelyn Bethel M, Feinglos MN.
    Med Clin North Am; 2004 Jul; 88(4):1085-105, xii. PubMed ID: 15308391
    [Abstract] [Full Text] [Related]

  • 19. The effects of pharmacologic agents for type 2 diabetes mellitus on body weight.
    Pi-Sunyer FX.
    Postgrad Med; 2008 Jul; 120(2):5-17. PubMed ID: 18654064
    [Abstract] [Full Text] [Related]

  • 20. Rational choice of oral antihyperglycaemic agents.
    Chowdhury S, Sengupta N.
    J Indian Med Assoc; 2002 Mar; 100(3):174-5, 177. PubMed ID: 12408278
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.